Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2424

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 2424
---
(c) Changes in Internal Control over Financial
Reporting

Other than described above, there
were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) during the year to which this Report relates that have materially affected or are reasonably likely to materially affect our internal
control over financial reporting. 

(d) Inherent Limitations on Effectiveness of Controls

Our disclosure controls and
procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control
objectives. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

Item 9B. Other Information.

Rule 10b5-1 Plan or non-Rule
10b5-1 Trading Arrangements

During the three-month period
ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended)
adopted, terminated or modified a Rule 10b5-1 trading arrangement or any “non-Rule 10b5-1 trading agreement” (as defined in
Item 408(c) of Regulation S-K).

Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections.

Not applicable.

111

PART III

Item 10. Directors, Executive Officers and
Corporate Governance.

The information required
under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement
will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2024.

Item 11. Executive Compensation.

The information required
under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement
will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2024.

Item 12. Security Ownership of Certain Beneficial
Owners and Management Related Stockholder Matters